Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says

MT Newswires Live02:22

Ocular Therapeutix (OCUL) shares have declined about 28% year to date, largely reflecting investor caution ahead of the pivotal SOL-1 readout, RBC Capital Markets said in a Wednesday note.

The firm said the timing of the SOL-1 data remains within guided timelines and an update was expected during the Q4 earnings call.

Ocular Therapeutix said Thursday that it will not be hosting Q4 conference call as it is currently observing a quiet period related to the anticipated data readout.

RBC said its internal trial simulations suggest SOL-1 can meet its primary endpoint under a range of scenarios.

The firm also pointed to data from the long-acting TKI class as supportive, citing phase 1 results showing 73% patients remained rescue-injection free for up to nine months.

RBC highlighted recent corporate actions, including the hiring of a new chief commercial officer with experience in retina, and the launch of two pivotal diabetic retinopathy studies.

RBC maintained its outperform rating on Ocular Therapeutix and a $30 price target.

Shares of Ocular Therapeutix were up nearly 7% in recent Thursday trading.

Price: 9.16, Change: +0.61, Percent Change: +7.13

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2609585081?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 02:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609585081","market":"us","top_or_hot":-1,"title":"Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> (OCUL) shares have declined about 28% year to date, largely reflecting investor caution ahead of the pivotal SOL-1 readout, RBC Capital Markets said in a Wednesday note.</p><p>The firm said the timing of the SOL-1 data remains within guided timelines and an update was expected during the Q4 earnings call.</p><p>Ocular Therapeutix said Thursday that it will not be hosting Q4 conference call as it is currently observing a quiet period related to the anticipated data readout.</p><p>RBC said its internal trial simulations suggest SOL-1 can meet its primary endpoint under a range of scenarios.</p><p>The firm also pointed to data from the long-acting TKI class as supportive, citing phase 1 results showing 73% patients remained rescue-injection free for up to nine months.</p><p>RBC highlighted recent corporate actions, including the hiring of a new chief commercial officer with experience in retina, and the launch of two pivotal diabetic retinopathy studies.</p><p>RBC maintained its outperform rating on Ocular Therapeutix and a $30 price target.</p><p>Shares of Ocular Therapeutix were up nearly 7% in recent Thursday trading.</p><p>Price: 9.16, Change: +0.61, Percent Change: +7.13</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcular Therapeutix's Recent Stock Weakness Presents Buying Opportunity, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-06 02:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/OCUL\">Ocular Therapeutix</a> (OCUL) shares have declined about 28% year to date, largely reflecting investor caution ahead of the pivotal SOL-1 readout, RBC Capital Markets said in a Wednesday note.</p><p>The firm said the timing of the SOL-1 data remains within guided timelines and an update was expected during the Q4 earnings call.</p><p>Ocular Therapeutix said Thursday that it will not be hosting Q4 conference call as it is currently observing a quiet period related to the anticipated data readout.</p><p>RBC said its internal trial simulations suggest SOL-1 can meet its primary endpoint under a range of scenarios.</p><p>The firm also pointed to data from the long-acting TKI class as supportive, citing phase 1 results showing 73% patients remained rescue-injection free for up to nine months.</p><p>RBC highlighted recent corporate actions, including the hiring of a new chief commercial officer with experience in retina, and the launch of two pivotal diabetic retinopathy studies.</p><p>RBC maintained its outperform rating on Ocular Therapeutix and a $30 price target.</p><p>Shares of Ocular Therapeutix were up nearly 7% in recent Thursday trading.</p><p>Price: 9.16, Change: +0.61, Percent Change: +7.13</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCUL","symbol_name":"Ocular Therapeutix","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2609585081","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609585081","pubTimestamp":1770315749,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ocular Therapeutix  shares have declined about 28% year to date, largely reflecting investor caution ahead of the pivotal SOL-1 readout, RBC Capital Markets said in a Wednesday note.The firm said the timing of the SOL-1 data remains within guided timelines and an update was expected during the Q4 earnings call.Ocular Therapeutix said Thursday that it will not be hosting Q4 conference call as it is currently observing a quiet period related to the anticipated data readout.RBC said its internal trial simulations suggest SOL-1 can meet its primary endpoint under a range of scenarios.The firm also pointed to data from the long-acting TKI class as supportive, citing phase 1 results showing 73% patients remained rescue-injection free for up to nine months.RBC highlighted recent corporate actions, including the hiring of a new chief commercial officer with experience in retina, and the launch of two pivotal diabetic retinopathy studies.RBC maintained its outperform rating on Ocular Therapeuti","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCUL":"Ocular Therapeutix","BK4007":"制药"},"translate_title":"加拿大皇家银行表示，Ocular Therapeutix近期股价疲软带来了买入机会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCUL":1.5},"content_text":"Ocular Therapeutix (OCUL) shares have declined about 28% year to date, largely reflecting investor caution ahead of the pivotal SOL-1 readout, RBC Capital Markets said in a Wednesday note.The firm said the timing of the SOL-1 data remains within guided timelines and an update was expected during the Q4 earnings call.Ocular Therapeutix said Thursday that it will not be hosting Q4 conference call as it is currently observing a quiet period related to the anticipated data readout.RBC said its internal trial simulations suggest SOL-1 can meet its primary endpoint under a range of scenarios.The firm also pointed to data from the long-acting TKI class as supportive, citing phase 1 results showing 73% patients remained rescue-injection free for up to nine months.RBC highlighted recent corporate actions, including the hiring of a new chief commercial officer with experience in retina, and the launch of two pivotal diabetic retinopathy studies.RBC maintained its outperform rating on Ocular Therapeutix and a $30 price target.Shares of Ocular Therapeutix were up nearly 7% in recent Thursday trading.Price: 9.16, Change: +0.61, Percent Change: +7.13","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2609585081","isCrawlerRequest":true}